Roles of poly ADP-ribose polymerase inhibitors in maintenance treatment for recurrent ovarian cancer

doi:10.3877/cma.j.issn.1673-5250.2021.01.001

Poly ADP-ribose polymerase inhibitor (PARPi), such as olaparib, rucaparib and niraparib are brand-new anticancer drugs with great potential. Through targeting intranuclear poly ADP-ribose polymerase (PARP), PARPi, which have made remarkable achievements in treatment of cancers, have the unique ability to selectively kill cancer cells with deficiency of homologous recombination repair pathway. However, clinical trial of rucaparib has been completed in China, and olaparib and niraparib have been approved by the National Medical Products Administration (NMPA) of China in 2019 for maintenance treatment of patients with relapsed ovarian cancers. We are still lack of clinical experience in application of PARPi. This article aims to give a comprehensive description of the suitable population, efficacy and safety of PARPi in treatment of ovarian cancers, in order to provide reference for their following widespread use.

Key words: Poly (ADP-ribose) polymerases, Poly (ADP-ribose) polymerase inhibitors, Ovarian neoplasms, Olaparib, Rucaparib, Niraparib, Maintenance therapy

[1]	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21492.
[2]	Wiggans AJ, Cass GK, Bryant A, et al. Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer [J]. Cochrane Database Syst Rev, 2015, (5): CD007929. DOI: 10.1002/14651858.CD007929.pub3.
[3]	Ledermann JA, Raja FA, Fotopoulou C, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J]. Ann Oncol, 2018, 29(Suppl 4): iv259. DOI: 10.1093/annonc/mdy157.
[4]	Bürkle A. Poly (ADP-ribose). The most elaborate metabolite of NAD⁺[J]. FEBS J, 2005, 272(18): 4576-4589. DOI: 10.1111/j.1742-4658.2005.04864.x.
[5]	Jain PG, Patel BD. Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update [J]. Eur J Med Chem, 2019, 165: 198-215. DOI: 10.1016/j.ejmech.2019.01.024.
[6]	Ashworth A, Lord CJ. Synthetic lethal therapies for cancer: what′s next after PARP inhibitors? [J]. Nat Rev Clin Oncol, 2018, 15(9): 564-576. DOI: 10.1038/s41571-018-0055-6.
[7]	Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial [J]. Lancet Oncol, 2014, 15(8): 852-861. DOI: 10.1016/S1470-2045(14)70228-1.
[8]	Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer [J]. N Engl J Med, 2016, 375(22): 2154-2164. DOI: 10.1056/NEJMoa1611310.
[9]	Swisher EM, Lin KK, Oza AM, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial [J]. Lancet Oncol, 2017, 18(1): 75-87. DOI: 10.1016/S1470-2045(16)30559-9.
[10]	Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer [J]. N Engl J Med, 2018, 379(26): 2495-2505. DOI: 10.1056/NEJMoa1810858.
[11]	Guo XX, Wu HL, Shi HY, et al. The efficacy and safety of olaparib in the treatment of cancers: a Meta-analysis of randomized controlled trials [J]. Cancer Manag Res, 2018, 10: 2553-2562. DOI: 10.2147/CMAR.S169558.
[12]	Qin W, Wu HJ, Cao LQ, et al. Research progress on PARP14 as a drug target [J]. Front Pharmacol, 2019, 10: 172. DOI: 10.3389/fphar.2019.00172.
[13]	Motegi A, Masutani M, Yoshioka KI, et al. Aberrations in DNA repair pathways in cancer and therapeutic significances [J]. Semin Cancer Biol, 2019, 58: 29-46. DOI: 10.1016/j.semcancer.2019.02.005.
[14]	Lee JY, Yi JY, Kim HS, et al. An umbrella study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG 3045), AMBITION [J]. Jpn J Clin Oncol, 2019, 49(8): 789-792. DOI: 10.1093/jjco/hyz085.
[15]	Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer [J]. N Engl J Med, 2019, 381(25): 2416-2428. DOI: 10.1056/NEJMoa1911361.
[16]	Coleman RL, Fleming GF, Brady MF, et al. Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer [J]. N Engl J Med, 2019, 381(25): 2403-2415. DOI: 10.1056/NEJMoa1909707.
[17]	González-Martín A, Pothuri B, Vergote I, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer [J]. N Engl J Med, 2019, 381(25): 2391-2402. DOI: 10.1056/NEJMoa1910962.
[18]	Mirza MR, Åvall Lundqvist E, Birrer MJ, et al. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial [J]. Lancet Oncol, 2019, 20(10): 1409-1419. DOI: 10.1016/S1470-2045(19)30515-7.
[19]	Pujade-Lauraine E, Ledermann JA, Selle F, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial [J]. Lancet Oncol, 2017, 18(9): 1274-1284. DOI: 10.1016/S1470-2045(17)30469-2.
[20]	LaFargue CJ, Dal Molin GZ, Sood AK, et al. Exploring and comparing adverse events between PARP inhibitors [J]. Lancet Oncol, 2019, 20(1): e15-e28. DOI: 10.1016/S1470-2045(18)30786-1.

[1]	Shihong Ma, Xiaoqin Li, Yanyun Shi. Diagnostic value of four types of risk of malignancy index in distinguishing benign and malignant ovarian tumors[J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2020, 17(11): 1108-1113.
[2]	Changsheng Lin, Jun Zhan, Xue Xiao. Genetic testing and precision molecular targeted therapy in diagnosis and treatment of epithelial ovarian caner[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(05): 505-510.
[3]	Xingchen Liu, Juan Liu, Baobao Wei, Jie Liu, Hui Liu. Correlation analysis of abnormal expression of XIAP and XAF1 with ovarian cancer[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(04): 419-427.
[4]	Huizhu Chen, Yingkun Guo, Xinrong Wang, Gang Ning, Xijian Chen. Current research status on the " dualistic model" of epithelial ovarian cancer and its molecular biology[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(04): 394-402.
[5]	Jie Deng, Yiran Wang, Ping Wang. Influencing factors of venous thromboembolism in women with ovarian clear cell carcinoma[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2022, 18(02): 150-157.
[6]	Lei Chu, Yi Guo, Xiaowen Tong. Research status of periostin in gynecological malignancies[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2022, 18(02): 145-149.
[7]	Chao Chen, Jinjuan Wang, Lin Li. Clinical characteristics of ovarian sclerosing stromal tumors[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2020, 16(04): 465-471.
[8]	Yimei Wu, Li Jin, Hefeng Huang. Research status of fertility preservation strategies in breast cancer patients[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2020, 16(02): 150-154.
[9]	Zhaolin Gong, Kemin Li, Rutie Yin. Current chemotherapy research status and consideration of early-stage epithelial ovarian cancer[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2020, 16(01): 16-22.
[10]	Qianying Zhao, Mingrong Qie. Pathological and molecular diagnosis of epithelial ovarian cancer[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2019, 15(06): 605-611.
[11]	Jing Jia, Xinlan Shi, Yuguang Li, Zhenqiang Li, Lei Sun. Ovarian seromucinous borderline tumors: a clinicopathological analysis and literature review[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2019, 15(05): 571-578.
[12]	Kang Wang, Xueting Hu, Hu Luo, Xiangdong Zhou. Retrospective study of EGFR-TKI combined with radiotherapy in maintenance therapy for advanced lung adenocarcinoma patients[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2021, 14(01): 17-23.
[13]	Xuhong Lu, Fan Hu, Ying Yang. Advances in the effects of poly (ADP-ribose) polymerases on adipocyte and energy metabolism[J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2022, 12(02): 100-104.
[14]	Yuxin Liu, Zihan Wang, Yixin Zhang, Yongjie Luan, Kai Meng. Research progress of Wilms' tumor gene 1 in the pathogenesis of ovarian diseases[J]. Chinese Journal of Diagnostics(Electronic Edition), 2023, 11(03): 178-183.
[15]	Kejun Wang, Jizhen Li, Biao Ma, Huichao Xu, Hongshan Shen, Lei Liu. Predictive value of creatinine/cystatin C on postoperative complications of advanced epithelial ovarian cancer[J]. Chinese Journal of Diagnostics(Electronic Edition), 2023, 11(01): 49-55.

Viewed

Full text

Abstract

Please choose a citation manager

Content to export